As of June 21, 2025, Flexion Therapeutics Inc (FLXN) reports a EV/EBITDA of -7.76.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Flexion Therapeutics Inc's EV/EBITDA to Peers
To better understand Flexion Therapeutics Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Flexion Therapeutics Inc (FLXN) | -7.76 |
| ADMA Biologics Inc (ADMA) | 26.73 |
| Abbvie Inc (ABBV) | 17.89 |
| Theratechnologies Inc (TH.TO) | 15.40 |
| Amgen Inc (AMGN) | 15.18 |
| Regeneron Pharmaceuticals Inc (REGN) | 12.56 |
Compared to its competitors, Flexion Therapeutics Inc's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.